ArticleFrontiers in oncology2026
The impact of sarcopenia and body mass index on treatment toxicity and survival in patients with extranodal natural killer/T-cell lymphoma: a retrospective analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia and body mass index (BMI) have been associated with treatment tolerance and prognosis in various malignancies; however, their clinical significance in extranodal natural killer/T-cell lymphoma (ENKTL) remains unclear. This study evaluated the impact of sarcopenia and BMI on treatment-related toxicities and survival outcomes in ENKTL. Methods: We retrospectively analyzed 347 patients with newly diagnosed ENKTL. Sarcopenia was assessed using sex-specific skeletal muscle index thresholds at the third lumbar vertebra level. BMI was categorized as underweight, normal weight, or overweight according to Asian-specific criteria. Associations with toxicities, overall survival (OS), and progression-free survival (PFS) were evaluated using regression and survival analyses. Results: Sarcopenia was identified in 113 patients (32.6%) and was associated with adverse clinical characteristics. Compared with non-sarcopenic patients, those with sarcopenia had significantly higher risks of hematological toxicity (RR = 1.15, 95% CI 1.06-1.24, Conclusion: Sarcopenia is independently associated with poorer overall survival and increased treatment-related toxicity in ENKTL. Low BMI further identifies patients at increased risk of adverse outcomes. Incorporating body composition assessment into routine clinical evaluation may improve risk stratification and supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.